Barclays Maintains an 'Equalweight' on Cardiome Pharma (CRME); Poor Visibility on Next Steps
Tweet Send to a Friend
Barclays maintains an 'Equalweight' on Cardiome Pharma (NASDAQ: CRME), PT $6.
Barclays analyst says, "We are maintaining our Equal Weight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "We are maintaining our Equal Weight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
